These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 23480466)

  • 21. How can high-throughput screening deliver drugs to treat atherosclerosis?
    Yang Y; Wang L; Si S; Hong B
    Expert Opin Drug Discov; 2010 Dec; 5(12):1175-88. PubMed ID: 22822720
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New biomarkers for lung cancer.
    Paci M; Rapicetta C; Maramotti S
    Expert Opin Med Diagn; 2010 May; 4(3):201-24. PubMed ID: 23488531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting NF-kappaB for colorectal cancer.
    Sakamoto K; Maeda S
    Expert Opin Ther Targets; 2010 Jun; 14(6):593-601. PubMed ID: 20367537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting TRPC6 channels in oesophageal carcinoma growth.
    Ding X; He Z; Shi Y; Wang Q; Wang Y
    Expert Opin Ther Targets; 2010 May; 14(5):513-27. PubMed ID: 20235901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma.
    Kaur A; Dasanu CA
    Expert Opin Pharmacother; 2011 Nov; 12(16):2493-503. PubMed ID: 21967344
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profile of new anticancer drugs.
    Mansi L; Thiery-Vuillemin A; Nguyen T; Bazan F; Calcagno F; Rocquain J; Demarchi M; Villanueva C; Maurina T; Pivot X
    Expert Opin Drug Saf; 2010 Mar; 9(2):301-17. PubMed ID: 20175699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapeutic targeting of EGFR in malignant gliomas.
    Ye F; Gao Q; Cai MJ
    Expert Opin Ther Targets; 2010 Mar; 14(3):303-16. PubMed ID: 20148717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future.
    Taylor M; Rössler J; Geoerger B; Vassal G; Farace F
    Expert Opin Investig Drugs; 2010 Jul; 19(7):859-74. PubMed ID: 20470190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging treatments for narcolepsy and its related disorders.
    Nishino S; Okuro M
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):139-58. PubMed ID: 20166851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer stem cell markers: what is their diagnostic value?
    Lin CY; Wang L; Than K; Marca FL; Park P
    Expert Opin Med Diagn; 2010 Nov; 4(6):473-81. PubMed ID: 23496228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccines as early therapeutic interventions for cancer therapy: neutralising the immunosuppressive tumour environment and increasing T cell avidity may lead to improved responses.
    Durrant LG; Pudney V; Spendlove I; Metheringham RL
    Expert Opin Biol Ther; 2010 May; 10(5):735-48. PubMed ID: 20384522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel inhibitors in development for hepatocellular carcinoma.
    Wörns MA; Galle PR
    Expert Opin Investig Drugs; 2010 May; 19(5):615-29. PubMed ID: 20374038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Parathyroid gland regulation: contribution of the in vivo and in vitro models.
    Carrillo-López N; Román-García P; Fernández-Martín JL; Cannata-Andía JB
    Expert Opin Drug Discov; 2010 Mar; 5(3):265-75. PubMed ID: 22823022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy regimens and treatment protocols for laryngeal cancer.
    Haigentz M; Silver CE; Hartl DM; Takes RP; Rodrigo JP; Robbins KT; Rinaldo A; Ferlito A
    Expert Opin Pharmacother; 2010 Jun; 11(8):1305-16. PubMed ID: 20429666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The somatostatin receptor subtype 5 in neuroendocrine tumours.
    van der Hoek J; Lamberts SW; Hofland LJ
    Expert Opin Investig Drugs; 2010 Mar; 19(3):385-99. PubMed ID: 20151855
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What does systems biology mean for biomarker discovery?
    Azuaje F
    Expert Opin Med Diagn; 2010 Jan; 4(1):1-10. PubMed ID: 23496106
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salivary biomarkers for periodontal disease diagnostics.
    Brinkmann O; Zhang L; Giannobile WV; Wong DT
    Expert Opin Med Diagn; 2011 Jan; 5(1):25-35. PubMed ID: 23484474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.